# A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

> **NCT00623428** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 235 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00623428
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2013-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623428, "A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00623428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*